The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma.
Composer and multiple myeloma survivor Ed Hartman shares how having creative outlets like music and writing have helped him manage the mental and physical impacts of his cancer diagnosis and treatment.
In this podcast, members of the American Society of Clinical Oncology (ASCO) discuss new research presented at the 2022 ASCO Annual Meeting in multiple myeloma, breast cancer, and cancer in people age 60 or older.
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include advances in treating HER2-low metastatic breast cancer, RAS wild-type metastatic colorectal cancer, recurrent and refractory Ewing sarcoma, and newly diagnosed multiple myeloma.
Dr. William Dale discusses 5 key studies presented at the SIOG 2020 Annual Meeting Online that involve improvements in evaluating, caring for, and treating people with cancer who are 60 or older.
The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include an effective medication for metastatic prostate cancer, targeted therapy that slows the growth of metastatic pancreatic cancer, how socioeconomic factors may affect survival for multiple myeloma, and how the ACA resulted in earlier treatment and improved equality in care.
Read research highlights that will be presented at the 2019 ASCO Annual Meeting, covering low-fat diets and risk of breast cancer death, chemotherapy for older adults with esophageal cancer, targeted therapy for those at risk for multiple myeloma, the rate of genetic changes in childhood cancers, and a new targeted therapy for childhood central nervous system tumors.
A bone marrow/stem cell transplant is an effective treatment option for several cancers, even when the patient is older. Read how you and your doctor can determine if the treatment is right for you.
The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?
